Skip to main content
. Author manuscript; available in PMC: 2010 May 1.
Published in final edited form as: Menopause. 2009;16(3):529–533. doi: 10.1097/gme.0b013e31818fb0c2

Figure 2. Comparison of HOXA13 mRNA expression in vaginal specimens.

Figure 2

Premenopausal controls n=6, Leuprolide acetate n=5, Premenopausal POP n=20, Postmenopausal POP n=25. Comparisons were made after normalization with beta actin. * indicates that expression of vaginal HOXA13 in groups is significantly different from the expression in the premenopausal controls and from specimens obtained from women treated with leuprolide acetate.